Recombinant GDF11
Recombinant GDF11 has been studied in 2 papers since 2020: 1 observational study in people, 1 in animals; 1 in the past year. The newest paper, Feb 25, 2026: “Elevated circulating GDF11 and its role in age-related sarcopenia: insights from clinical, transcriptomic, and in vitro analyses”.
2 papers study it3 findingsUpdated
- 2 independent labs in 1 country
- Funders: International Team for Implantology and 1 more
- Humans1
- Animals1
What did studies of Recombinant GDF11 find?
3Studies of Recombinant GDF11 measured 3 outcomes; the most studied are ubiquitin–proteasome system (1 study), trabecular bone volume (1) and implant fixation (1).
Ubiquitin–proteasome system
upin mouse cells1
1 study
Ubiquitin–proteasome system
upin mouse cells1
Recombinant GDF11 activates ubiquitin–proteasome system in mouse cells.
“rGDF11 treatment activated SMAD3 phosphorylation and induced a dose-dependent upregulation of Atrogin-1 and MuRF1”
Cellsin differentiated C2C12 myotubesmyotubes
Frontiers in aging
Trabecular bone volume
downin mice1
1 study
Trabecular bone volume
downin mice1
Recombinant GDF11 decreases trabecular bone volume in mice.
“rGDF11 administration resulted in less trabecular bone volume and thinner cortical thickness in the mandible”
Animalsrecombinant GDF11 (rGDF11)mandible6 weeksmales
Journal of periodontology
Implant fixation
downin mice1
1 study
Implant fixation
downin mice1
Recombinant GDF11 impairs implant fixation in mice.
“supraphysiologic GDF11 leads to a significantly decreased bone-to-implant contact ratio (BIC) and peri-implant bone volume/total volume (BV/TV) at the histologic level and reduced resistance at the biomechanical level”
Animalsrecombinant GDF11 (rGDF11)femur6 weeksmales
Journal of periodontology